Dimethyltryptamine

Dimethyltryptamine

kstrassman.com/index.php?option=com_content&view=article&id=61&Itemid=60" class="external text" rel="nofollow">"Chapter summaries". Retrieved 27 February 2012. )
  • ^ a b c  
  • ^ Pachter I.J., Zacharias D.E., Ribeiro O. (September 1959). "Indole alkaloids of Acer saccharinum (the silver maple), Dictyoloma incanescens, Piptadenia colubrina, and Mimosa hostilis". Journal of Organic Chemistry 24 (9): 1285–87.  
  • ^ Fish M.S., Johnson N.M., Horning E.C. (November 1955). "Piptadenia alkaloids. Indole bases of P. peregrina (L.) Benth. and related species". Journal of the American Chemical Society 72 (22): 5892–95.  
  • ^ Cimino G., De Stefano S. (1978). "Chemistry of Mediterranean gorgonians: simple indole derivatives from Paramuricea chamaeleon". Comparative Biochemistry and Physiology Part C: Comparative Pharmacology 61 (2): 361–2.  
  • ^ Hochstein F.A., Paradies A.M. (1957). "Prestonia amazonicum and Banisteria caapi"Alkaloids of . Journal of the American Chemical Society 79 (21): 5735–36.  
  • ^ Schultes R.E., Raffauf R.F. (1960). : An Amazon narcotic or not?"Prestonia". Botanical Museum Leaflets, Harvard University 19 (5): 109–122.  
  • ^ a b Poisson J. (April 1965). "Note sur le "Natem", boisson toxique péruvienne et ses alcaloïdes" [Note on "Natem", a toxic Peruvian beverage, and its alkaloids]. Annales Pharmaceutiques Françaises (in French) 23: 241–4.  
  • ^ Der Marderosian A.H., Kensinger K.M., Chao J.-M., Goldstein F.J. (1970). "The use and hallucinatory principles of a psychoactive beverage of the Cashinahua tribe (Amazon basin)". Drug Dependence 5: 7–14.  
  • ^ a b c Axelrod J. (August 1961). "Enzymatic formation of psychotomimetic metabolites from normally occurring compounds". Science 134 (3475): 343.  
  • ^ a b c d e f g h i Rosengarten H., Friedhoff A.J. (1976). "A review of recent studies of the biosynthesis and excretion of hallucinogens formed by methylation of neurotransmitters or related substances" (PDF). Schizophrenia Bulletin 2 (1): 90–105.  
  • ^ a b c d e f Barker S.A., Monti J.A., Christian S.T. (1981). "N, N-dimethyltryptamine: an endogenous hallucinogen". International Review of Neurobiology. International Review of Neurobiology 22: 83–110.  
  • ^ Lin R.L., Narasimhachari N., Himwich H.E. (September 1973). "Inhibition of indolethylamine-N-methyltransferase by S-adenosylhomocysteine". Biochemical and Biophysical Research Communications 54 (2): 751–9.  
  • ^ a b c d e Thompson M.A., Weinshilboum R.M. (December 1998). -methyltransferase. cDNA and gene cloning and characterization"N"Rabbit lung indolethylamine . Journal of Biological Chemistry 273 (51): 34502–10.  
  • ^ a b Mandel L.R., Prasad R., Lopez-Ramos B., Walker R.W. (January 1977). "The biosynthesis of dimethyltryptamine in vivo". Research Communications in Chemical Pathology and Pharmacology 16 (1): 47–58.  
  • ^ a b c d e f g h Thompson M.A., Moon E., Kim U.J., Xu J., Siciliano M.J., Weinshilboum R.M. (November 1999). -methyltransferase: cDNA cloning and expression, gene cloning, and chromosomal localization"N"Human indolethylamine (PDF). Genomics 61 (3): 285–97.  
  • ^ a b c d e f g h i j k l m n Kärkkäinen J., Forsström T., Tornaeus J., Wähälä K., Kiuru P., Honkanen A., Stenman U.-H., Turpeinen U., Hesso A. (April 2005). "Potentially hallucinogenic 5-hydroxytryptamine receptor ligands bufotenine and dimethyltryptamine in blood and tissues". Scandinavian Journal of Clinical and Laboratory Investigation 65 (3): 189–199.  
  • ^ a b Barker SA, Borjigin J, Lomnicka I, Strassman R (Jul 2013). "LC/MS/MS analysis of the endogenous dimethyltryptamine hallucinogens, their precursors, and major metabolites in rat pineal gland microdialysate". Biomed Chromatogr.  
  • ^ Gomes MM, Coimbra JB, Clara RO, Dörr FA, Moreno AC, Chagas JR, Tufik S, Pinto E Jr, Catalani LH, Campa A. (2014). "Biosynthesis of N,N-dimethyltryptamine (DMT) in a melanoma cell line and its metabolization by peroxidases". Biochemica Pharmacology. 88 (3): 393–401.  
  • ^ Szabo A, Kovacs A, Frecska E, Rajnavolgyi E. (29 Aug 2014). "Psychedelic N,N-Dimethyltryptamine and 5-Methoxy-N,N-Dimethyltryptamine Modulate Innate and Adaptive Inflammatory Responses through the Sigma-1 Receptor of Human Monocyte-Derived Dendritic Cells". PLoS ONE 9 (8): e106533.  
  • ^ Mandel L.R., Rosenzweig S., Kuehl F.A. (March 1971). "Purification and substrate specificity of indoleamine-N-methyl transferase". Biochemical Pharmacology 20 (3): 712–6.  
  • ^ Lin R.-L., Narasimhachari N. (June 1975). "N-methylation of 1-methyltryptamines by indolethylamine N-methyltransferase". Biochemical Pharmacology 24 (11–12): 1239–40.  
  • ^ Mandel L.R., Ahn H.S., VandenHeuvel W.J. (April 1972). "Indoleamine-N-methyl transferase in human lung". Biochemical Pharmacology 21 (8): 1197–200.  
  • ^ Rosengarten H., Meller E., Friedhoff A.J. (1976). "Possible source of error in studies of enzymatic formation of dimethyltryptamine". Journal of Psychiatric Research 13 (1): 23–30.  
  • ^ Morgan M., Mandell A.J. (August 1969). "Indole(ethyl)amine N-methyltransferase in the brain". Science 165 (3892): 492–3.  
  • ^ Mandell A.J., Morgan M. (March 1971). "Indole(ethyl)amine N-methyltransferase in human brain". Nature: New Biology 230 (11): 85–7.  
  • ^ Saavedra J.M., Coyle J.T., Axelrod J. (March 1973). "The distribution and properties of the nonspecific N-methyltransferase in brain". Journal of Neurochemistry 20 (3): 743–52.  
  • ^ Saavedra J.M., Axelrod J. (March 1972). "Psychotomimetic N-methylated tryptamines: formation in brain in vivo and in vitro" (PDF). Science 175 (4028): 1365–6.  
  • ^ Wu P.H., Boulton A.A. (July 1973). "Distribution and metabolism of tryptamine in rat brain". Canadian Journal of Biochemistry 51 (7): 1104–12.  
  • ^ Boarder M.R., Rodnight R. (September 1976). "Tryptamine-N-methyltransferase activity in brain tissue: a re-examination". Brain Research 114 (2): 359–64.  
  • ^ Gomes U.R., Neethling A.C., Shanley B.C. (September 1976). "Enzymatic N-methylation of indoleamines by mammalian brain: fact or artefact?". Journal of Neurochemistry 27 (3): 701–5.  
  • ^ Stramentinoli G., Baldessarini R.J. (October 1978). "Lack of enhancement of dimethyltryptamine formation in rat brain and rabbit lung  
  • ^ a b c d General annotation of Human INMT (O95050) entry in UniProtKB/Swiss-Prot
  • ^ a b Cozzi N.V., Mavlyutov T.A., Thompson M.A., Ruoho A.E. (2011). "Indolethylamine N-methyltransferase expression in primate nervous tissue" (PDF). Society for Neuroscience Abstracts 37: 840.19. 
  • ^ Franzen F., Gross H. (June 1965). "Tryptamine, N,N-dimethyltryptamine, N,N-dimethyl-5-hydroxytryptamine and 5-methoxytryptamine in human blood and urine". Nature 206 (988): 1052.  
  • ^ Siegel M. (October 1965). "A sensitive method for the detection of N,N-dimethylserotonin (bufotenin) in urine; failure to demonstrate its presence in the urine of schizophrenic and normal subjects". Journal of Psychiatric Research 3 (3): 205–11.  
  • ^ Barker S.A., Littlefield-Chabaud M.A., David C. (February 2001). "Distribution of the hallucinogens N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine in rat brain following intraperitoneal injection: application of a new solid-phase extraction LC-APcI-MS-MS-isotope dilution method". Journal of Chromatography B 751 (1): 37–47.  
  • ^ a b c Forsström T., Tuominen J., Karkkäinen J. (2001). "Determination of potentially hallucinogenic N-dimethylated indoleamines in human urine by HPLC/ESI-MS-MS". Scandinavian Journal of Clinical and Laboratory Investigation 61 (7): 547–56.  
  • ^ Shen H.W., Jiang X.L., Yu A.M. (April 2009). "Development of a LC-MS/MS method to analyze 5-methoxy-N,N-dimethyltryptamine and bufotenine, and application to pharmacokinetic study". Bioanalysis 1 (1): 87–95.  
  • ^ Wyatt R.J., Mandel L.R., Ahn H.S., Walker R.W., Vanden Heuvel W.J. (July 1973). "Gas chromatographic-mass spectrometric isotope dilution determination of N,N-dimethyltryptamine concentrations in normals and psychiatric patients" (PDF). Psychopharmacologia 31 (3): 265–70.  
  • ^ Angrist B., Gershon S., Sathananthan G., Walker R.W., Lopez-Ramos B., Mandel L.R., Vandenheuvel W.J. (May 1976). %7CFormat PDF "Dimethyltryptamine levels in blood of schizophrenic patients and control subjects". Psychopharmacology 47 (1): 29–32.  
  • ^ Oon M.C., Rodnight R. (December 1977). "A gas chromatographic procedure for determining N, N-dimethyltryptamine and N-monomethyltryptamine in urine using a nitrogen detector". Biochemical Medicine 18 (3): 410–9.  
  • ^ a b Smythies J.R., Morin R.D., Brown G.B. (June 1979). "Identification of dimethyltryptamine and O-methylbufotenin in human cerebrospinal fluid by combined gas chromatography/mass spectrometry". Biological Psychiatry 14 (3): 549–56.  
  • ^ a b Christian S.T., Harrison R., Quayle E., Pagel J., Monti J. (October 1977). "The in vitro identification of dimethyltryptamine (DMT) in mammalian brain and its characterization as a possible endogenous neuroregulatory agent". Biochemical Medicine 18 (2): 164–83.  
  • ^ Erowid (14 February 1999). "5-MeO-DMT dosage". Erowid 5-MeO-DMT Vault. Retrieved 8 December 2010. 
  • ^ a b Kaplan J., Mandel L.R., Stillman R., Walker R.W., VandenHeuvel W.J., Gillin J.C., Wyatt R.J. (1974). "Blood and urine levels of N,N-dimethyltryptamine following administration of psychoactive dosages to human subjects" (PDF). Psychopharmacologia 38 (3): 239–45.  
  • ^ a b c d Strassman R.J., Qualls C.R. (February 1994). "Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects". Archives of General Psychiatry 51 (2): 85–97.  
  • ^ Barker S.A., Beaton J.M., Christian S.T., Monti J.A., Morris P.E. (August 1982). "Comparison of the brain levels of N,N-dimethyltryptamine and α, α, β, β-tetradeutero-N-N-dimethyltryptamine following intraperitoneal injection. The in vivo kinetic isotope effect".  
  • ^ Sangiah S., Gomez M.V., Domino E.F. (December 1979). "Accumulation of N,N-dimethyltryptamine in rat brain cortical slices". Biological Psychiatry 14 (6): 925–36.  
  • ^ Sitaram B.R., Lockett L., Talomsin R., Blackman G.L., McLeod W.R. (May 1987). "In vivo metabolism of 5-methoxy-N,N-dimethyltryptamine and N,N-dimethyltryptamine in the rat". Biochemical Pharmacology 36 (9): 1509–12.  
  • ^ Takahashi T., Takahashi K., Ido T., Yanai K., Iwata R., Ishiwata K., Nozoe S. (December 1985). "[11C]-labeling of indolealkylamine alkaloids and the comparative study of their tissue distributions". International Journal of Applied Radiation and Isotopes 36 (12): 965–9.  
  • ^ Yanai K., Ido T., Ishiwata K., Hatazawa J, Takahashi T., Iwata R., Matsuzawa T. (1986). C)dimethyltryptamine"11-(N,N kinetics and displacement study of a carbon-11-labeled hallucinogen, In vivo" (PDF). European Journal of Nuclear Medicine 12 (3): 141–6.  
  • ^ a b Best J, Nijhout HF, Reed M (2010). "Serotonin synthesis, release and reuptake in terminals: a mathematical model". Theoretical Biology & Medical Modelling 7: 34.  
  • ^ a b Merrill MA, Clough RW, Jobe PC, Browning RA (September 2005). "Brainstem seizure severity regulates forebrain seizure expression in the audiogenic kindling model" (PDF). Epilepsia 46 (9): 1380–8.  
  • ^ Callaway J.C., McKenna D.J., Grob C.S., Brito G.S., Raymon L.P., Poland R.E., Andrade E.N. et al. (June 1999). alkaloids in healthy humans"Hoasca"Pharmacokinetics of (PDF). Journal of Ethnopharmacology 65 (3): 243–56.  
  • ^ Riba J., Valle M., Urbano G., Yritia M., Morte A., Barbanoj M.J. (July 2003). "Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics" (PDF). Journal of Pharmacology and Experimental Therapeutics 306 (1): 73–83.  
  • ^ a b c d e f g h i j k l Keiser M.J., Setola V., Irwin J.J., Laggner C., Abbas A.I., Hufeisen S.J., Jensen N.H. et al. (November 2009). "Predicting new molecular targets for known drugs". Nature 462 (7270): 175–81.  
  • ^ a b Deliganis A.V., Pierce P.A., Peroutka S.J. (June 1991). "Differential interactions of dimethyltryptamine (DMT) with 5-HT1A and 5-HT2 receptors". Biochemical Pharmacology 41 (11): 1739–44.  
  • ^ a b c d e Pierce P.A., Peroutka S.J. (1989). "Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex" (PDF). Psychopharmacology 97 (1): 118–22.  
  • ^ a b c d e f g h i j k l Ray T.S. (2010). Manzoni, Olivier Jacques, ed. "Psychedelics and the Human Receptorome". PLoS ONE 5 (2): e9019.  
  • ^ a b c d e Smith R.L., Canton H., Barrett R.J., Sanders-Bush E. (November 1998). receptors"2C and 5-HT2A-dimethyltryptamine at serotonin 5-HTN,N"Agonist properties of (PDF). Pharmacology, Biochemistry, and Behavior 61 (3): 323–30.  
  • ^ Rothman R.B., Baumann M.H. (May 2009). "Serotonergic Drugs and Valvular Heart Disease" (PDF). Expert Opinion on Drug Safety 8 (3): 317–29.  
  • ^ Roth B.L. (January 2007). "Drugs and valvular heart disease". New England Journal of Medicine 356 (1): 6–9.  
  • ^ Jonathan D. Urban, William P. Clarke, Mark von Zastrow, David E. Nichols, Brian Kobilka, Harel Weinstein, Jonathan A. Javitch, Bryan L. Roth, Arthur Christopoulos, Patrick M. Sexton, Keith J. Miller, Michael Spedding and Richard B. Mailman (2006-06-27). "Functional Selectivity and Classical Concepts of Quantitative Pharmacology". JPET 320 (1): 1–13.  
  • ^ Burchett, Scott A.; Hicks, T. Philip (August 2006). "The mysterious trace amines: Protean neuromodulators of synaptic transmission in mammalian brain" (PDF). Progress in Neurobiology 79 (5–6): 223–46.  
  • ^ a b c Fontanilla D., Johannessen M., Hajipour A.R., Cozzi N.V., Jackson M.B., Ruoho A.E. (February 2009). "The Hallucinogen N,N-Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator". Science 323 (5916): 934–7.  
  • ^ a b Cozzi N.V., Gopalakrishnan A., Anderson L.L., Feih J.T., Shulgin A.T., Daley P.F., Ruoho A.E. (December 2009). "Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter" (PDF). Journal of Neural Transmission 116 (12): 1591–9.  
  • ^ Glennon, R.A. (1994). "Classical hallucinogens: an introductory overview". In Lin, G.C.; Glennon, R.A. Hallucinogens: An Update. NIDA Research Monograph Series 146. Rockville, MD: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Institute on Drug Abuse. p. 4. 
  • ^ Fantegrossi W.E., Murnane K.S., Reissig C.J. (January 2008). "The behavioral pharmacology of hallucinogens" (PDF). Biochemical Pharmacology 75 (1): 17–33.  
  • ^ a b c Nichols D.E. (February 2004). "Hallucinogens". Pharmacology & Therapeutics 101 (2): 131–81.  
  • ^ Vollenweider F.X., Vollenweider-Scherpenhuyzen M.F., Bäbler A., Vogel H., Hell D. (December 1998). "Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action". NeuroReport 9 (17): 3897–902.  
  • ^ a b Strassman R.J. (1996). "Human psychopharmacology of N,N-dimethyltryptamine" (PDF). Behavioural Brain Research 73 (1–2): 121–4.  
  • ^ Glennon R.A., Titeler M., McKenney J.D. (December 1984). "Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents". Life Sciences 35 (25): 2505–11.  
  • ^ Roth B.L., Choudhary M.S., Khan N., Uluer A.Z. (February 1997). receptors: evidence in favor of a modified ternary complex model"2A"High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine (PDF). Journal of Pharmacology and Experimental Therapeutics 280 (2): 576–83.  
  • ^ Canal C.E., Olaghere da Silva U.B., Gresch P.J., Watt E.E., Sanders-Bush E., Airey D.C. (April 2010). "The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen" (PDF). Psychopharmacology 209 (2): 163–74.  
  • ^ a b Su T.P., Hayashi T., Vaupel D.B. (2009). "When the Endogenous Hallucinogenic Trace Amine N,N-Dimethyltryptamine Meets the Sigma-1 Receptor" (PDF). Science Signaling 2 (61): pe12.  
  • ^ Morinan A., Collier J.G. (1981). "Effects of pargyline and SKF-525A on brain N,N-dimethyltryptamine concentrations and hyperactivity in mice". Psychopharmacology 75 (2): 179–83.  
  • ^ Bruns D., Riedel D., Klingauf J., Jahn R. (October 2000). "Quantal release of serotonin". Neuron 28 (1): 205–20.  
  • ^ a b c Torres, Constantino Manuel; Repke, David B. (2006). Anadenanthera: Visionary Plant Of Ancient South America. Binghamton, NY: Haworth Herbal. pp. 107–122.  
  • ^ Rivier, Laurent; Lindgren, Jan-Erik (1972). "'Ayahuasca,' the South American hallucinogenic drink: An ethnobotanical and chemical investigation". Economic Botany 26 (2): 101–129.  
  • ^ McKenna, Dennis J.; Towers, G.H.N.; Abbott, F. (1984). "Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and β-carboline constituents of Ayahuasca". Journal of Ethnopharmacology 10 (2): 195–223.  
  • ^ Ott J. (2001). "Pharmañopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine" (PDF). Journal of Psychoactive Drugs 33 (3): 273–81.  
  • ^ Rick Strassman (2001). Dmt: the Spirit Molecule: A Doctor's Revolutionary Research into the Biology of near-Death and Mystical Experiences. pp. 187–8, also pp.173–4.  
  • ^ McKenna, Terence (1975), The Invisible Landscape: Mind, Hallucinogens and the I Ching 
  • ^ Hanks, Micah A. (10 September 2010), Causal Multiplicity: The Science Behind Schizophrenia 
  • ^ Luke, D. (2011), "Discarnate entities and dimethyltryptamine (DMT): Psychopharmacology, phenomenology and ontology.", Journal of the Society for Psychical Research 75 (902): 26–42 
  • ^ Luke, D. P. (2012), "Psychoactive substances and paranormal phenomena: A comprehensive review.", International Journal of Transpersonal Studies 31: 97–156 
  • ^ Pickover, Cliff (2005). Sex, Drugs, Einstein, and Elves: Sushi, Psychedelics, Parallel Universes, and the Quest for Transcendence. Smart Publications.  
  • ^ Haroz, Rachel; Greenberg, Michael I. (November 2005). "Emerging Drugs of Abuse". Medical Clinics of North America (Philadelphia:  
  • ^ a b Callaway, James C.; Grob, Charles S. (1998). "Ayahuasca Preparations and Serotonin Reuptake Inhibitors: A Potential Combination for Severe Adverse Interactions" (PDF). Journal of Psychoactive Drugs 30 (4): 367–9.  
  • ^ Bergström, Mats; Westerberg, Göran; Långström, Bengt (1997). "11C-harmine as a tracer for monoamine oxidase A (MAO-A): In vitro and in vivo studies". Nuclear Medicine and Biology 24 (4): 287–293.  
  • ^ Andritzky, Walter (1989). "Sociopsychotherapeutic Functions of Ayahuasca Healing in Amazonia". Journal of Psychoactive Drugs 21 (1): 77–89.  
  • ^ https://articles/Mimosa_tenuiflora#Entheogenic_uses Concentration of DMT in Mimosa Tenuiflora
  • ^ "2C-B, DMT, You and Me". Maps. Retrieved 2007-01-13. 
  • ^ "Entheogens & Visionary Medicine Pages". Miqel.com. Retrieved 2007-08-17. 
  • ^ Callaway JC, Raymon LP, Hearn WL Quantitation of N,N-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with ayahuasca (1996). "Quantitation of N,N-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with ayahuasca". J. Anal. Toxicol. 20 (6): 492–497.  
  • ^ R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 9th edition, Biomedical Publications, Seal Beach, CA, 2011, pp. 525–526.
  • ^ Robert S. Gable (2007). "Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids". Addiction 102 (1): 24–34.  
  • ^ "'"DMT: The psychedelic drug 'produced in your brain. SBS. 8 November 2013. Retrieved 27 March 2014. 
  • ^ Wallach J V (2009). "Endogenous hallucinogens as ligands of the trace amine receptors: a possible role in sensory perception.". Med Hypotheses. 72 (1): 91–4.  
  • ^ "The God Chemical: Brain Chemistry And Mysticism". NPR. Retrieved 2012-09-20. 
  • ^ Callaway J (1988). "A proposed mechanism for the visions of dream sleep". Med Hypotheses 26 (2): 119–24.  
  • ^ Wallach J V (2009). "Endogenous hallucinogens as ligands of the trace amine receptors: a possible role in sensory perception.". Med Hypotheses. 72 (1): 91–4.  
  • ^ Hoffer A., Osmond H., Smythies J.; Osmond; Smythies (January 1954). "Schizophrenia; a new approach. II. Result of a year's research". Journal of Mental Science 100 (418): 29–45.  
  • ^ Schaepe, Herbert (2001). """International control of the preparation "ayahuasca (JPG). Erowid. Retrieved November 29, 2010. 
  • ^ "Consultation on implementation of model drug schedules for Commonwealth serious drug offences".  
  • ^ http://connection.ebscohost.com/c/articles/79564875/aussie-dmt-ban
  • ^ Berry, Michael;  
  • ^ "Schedule 1: Class A controlled drugs". Misuse of Drugs Act 1975.  
  • ^ Church of the Holy Light of the Queen v. Mukasey
  • ^ Church of the Holy Light of the Queen v. Mukasey (D. Ore. 2009) (“permanently enjoins Defendants from prohibiting or penalizing the sacramental use of Daime tea by Plaintiffs during Plaintiffs' religious ceremonies”). Text